Video Experimental Relacionado
Updated: Sep 9, 2025
04:38
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
15.8K
[Colangitis biliar primaria - Actualización del diagnóstico, estratificación del riesgo y nuevas opciones de
Toni Herta1,2, Thomas Berg3
1Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum und Campus Charité Mitte, Augustenburger Platz 1, 13353, Berlin, Deutschland. toni.herta@charite.de.
Innere Medizin (Heidelberg, Germany)
|September 4, 2025
Resumen
Los nuevos agonistas de los receptores activados por el proliferador peroxisómico (PPAR) ofrecen mejores opciones de tratamiento para los pacientes con colangitis biliar primaria (CBP) que no responden al ácido ursodeoxicólico. Estos agentes son prometedores en el manejo de la colestasis y el prurito, mejorando la atención al paciente.
Área de la Ciencia:
- Hepatología
- Inmunología
- Farmacología
Sus antecedentes:
- La colangitis biliar primaria (CBP) es una enfermedad hepática autoinmune crónica.
- El ácido ursodeoxicólico (UDCA) es el tratamiento de primera línea, pero el 40% de los pacientes tienen una respuesta inadecuada.
- El manejo de los síntomas, especialmente el prurito, es crucial en el tratamiento de la CBP.
Objetivo del estudio:
- Proporcionar una actualización completa sobre el diagnóstico, la estratificación del riesgo y el tratamiento del cáncer de próstata.
- Centrarse en el papel de los nuevos agonistas de los receptores activados por el proliferador peroxisómico (PPAR) en la terapia de segunda línea.
- Discutir estrategias prácticas para el manejo del prurito en pacientes con CBP.
Principales métodos:
- Revisión de la literatura actual sobre el diagnóstico y el tratamiento del CBC.
- Análisis de los datos de ensayos clínicos para los nuevos agonistas de los PPAR (elafibranor, seladelpar).
- Discusión sobre el uso fuera de etiqueta del bezafibrato como agonista de los PPAR.
Principales resultados:
- Los nuevos agonistas de PPAR (elafibranor, seladelpar) muestran una fuerte eficacia bioquímica y un perfil de seguridad favorable.
- El bezafibrato es una opción establecida para mejorar la colestasis y el prurito.
- Las estrategias de diagnóstico y estratificación de riesgos actualizadas son esenciales para el manejo óptimo de los pacientes.
Conclusiones:
- Los nuevos agonistas de PPAR representan un avance significativo en el tratamiento de segunda línea para el CBC.
- Los conceptos de tratamiento individualizados y los ajustes oportunos son clave para mejorar los resultados de los pacientes.
- El tratamiento eficaz del prurito sigue siendo un objetivo terapéutico crítico en la CBP.
Videos de Conceptos Relacionados
01:29Chronic Pancreatitis II: Collaborative Care
127
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
127
01:17Chronic Bowel Disorders: Introduction
536
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
536
01:30Acute Pancreatitis II: Clinical Manifestations and Management
173
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
173
01:26Diseases of the Liver and Gallbladder
957
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
957
01:24Chronic Pancreatitis I: Introduction
147
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
147
01:29Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177